Jacobio Pharmaceuticals Advances Cancer Drug Pipeline with Strategic Licensing and Trials

Jacobio Pharmaceuticals Group Co., Ltd. ( (HK:1167) ) has issued an announcement.

Jacobio Pharmaceuticals has announced significant progress in its drug development pipeline, including the submission of a New Drug Application for glecirasib for second-line NSCLC in China and the initiation of pivotal trials for other cancer types. The company has licensed the Greater China rights of glecirasib and sitneprotafib to Allist, securing a deal worth RMB900 million plus royalties, and launched first-in-human trials in the U.S. and China, reinforcing its position as a leader in the global R&D biotech space.

More about Jacobio Pharmaceuticals Group Co., Ltd.

Jacobio Pharmaceuticals Group Co., Ltd. is a biotech company focused on innovation-driven global research and development, particularly in the RAS space. The company specializes in developing treatments for various cancers, including non-small cell lung cancer (NSCLC) and pancreatic ductal adenocarcinoma (PDAC), and it has a strong market focus on China and the U.S.

YTD Price Performance: 122.05%

Average Trading Volume: 4,603,490

Technical Sentiment Consensus Rating: Sell

Current Market Cap: HK$2.23B

For detailed information about 1167 stock, go to TipRanks’ Stock Analysis page.